HUMSTARD 30/70: Detailed Overview
Description
The medicine, HUMSTARD 30/70, is a combination of insulin isophane/NPH (70%) and human insulin/soluble insulin (30%). It is manufactured by CADILA and is categorized as Uncategorised. HUMSTARD 30/70 is available in injection form in a 10mL vial. The actual MRP of the medicine is Rs. 174.78, but it is currently being sold at a discounted price of Rs. 119, with a discount of 31.91%.
Active Ingredients
– Insulin Isophane/NPH (70%)
– Human Insulin/Soluble Insulin (30%)
Pharmacological Properties
HUMSTARD 30/70 combines the properties of insulin isophane/NPH and human insulin/soluble insulin to help regulate blood sugar levels in patients with diabetes. Insulin isophane/NPH has an intermediate-acting effect, providing a longer duration of action, while human insulin/soluble insulin acts more rapidly to lower blood glucose levels.
Indications
HUMSTARD 30/70 is indicated for the management of diabetes in patients who require insulin therapy to control their blood sugar levels. It is used to help regulate glucose levels in individuals with type 1 and type 2 diabetes.
Contraindications
– Hypersensitivity to insulin or any of the ingredients in HUMSTARD 30/70
– Hypoglycemia (low blood sugar)
– Diabetic ketoacidosis
Dosage
The dosage of HUMSTARD 30/70 may vary depending on the individual patient’s needs and their healthcare provider’s recommendations. It is typically administered subcutaneously, as directed by a healthcare professional.
Side Effects
Common side effects of HUMSTARD 30/70 may include:
– Hypoglycemia
– Injection site reactions (redness, swelling, or itching)
– Weight gain
Severe side effects may include:
– Severe hypoglycemia
– Allergic reactions
Drug Interactions
HUMSTARD 30/70 may interact with the following medications:
– Oral hypoglycemic agents
– Beta-blockers
– ACE inhibitors
– Thiazolidinediones
It is important to inform your healthcare provider about all the medications you are taking to avoid potential drug interactions.
Patient Counseling
Patients using HUMSTARD 30/70 should be counseled on the following:
– Proper administration technique
– Blood glucose monitoring
– Symptoms of hypoglycemia and hyperglycemia
– Diet and exercise recommendations
Clinical Evidence
Clinical studies have demonstrated the efficacy and safety of HUMSTARD 30/70 in helping patients with diabetes achieve and maintain target blood glucose levels. Consult your healthcare provider for more information on the clinical evidence supporting the use of this medication.
Frequently Asked Questions (FAQs)
Q: How should I store HUMSTARD 30/70?
A: HUMSTARD 30/70 should be stored in the refrigerator at a temperature between 2°C to 8°C. Do not freeze the medication.
Q: Can I mix HUMSTARD 30/70 with other insulins?
A: It is not recommended to mix HUMSTARD 30/70 with other insulins without consulting a healthcare professional.
Q: What should I do if I miss a dose of HUMSTARD 30/70?
A: If you miss a dose of HUMSTARD 30/70, contact your healthcare provider for instructions on how to proceed.
Q: Are there any dietary restrictions while using HUMSTARD 30/70?
A: Follow your healthcare provider’s dietary recommendations while using HUMSTARD 30/70 to help manage your blood sugar levels effectively.
Q: How quickly does HUMSTARD 30/70 work after administration?
A: The onset of action of HUMSTARD 30/70 may vary but typically starts working within 30 minutes to 1 hour after administration.
Q: What should I do if I experience side effects from HUMSTARD 30/70?
A: If you experience any side effects while using HUMSTARD 30/70, contact your healthcare provider immediately for further evaluation and guidance.
Q: Can I adjust the dosage of HUMSTARD 30/70 on my own?
A: Do not adjust the dosage of HUMSTARD 30/70 without consulting your healthcare provider as it may lead to complications in managing your diabetes.
By providing comprehensive information on HUMSTARD 30/70, including its active ingredients, pharmacological properties, indications, contraindications, dosage, side effects, drug interactions, patient counseling, clinical evidence, and frequently asked questions, patients can make informed decisions about their diabetes management. It is essential to follow healthcare provider recommendations and guidelines for the safe and effective use of HUMSTARD 30/70.
